Wyeth Will Seek Rapamune Post-Transplant Regimen Without Cyclosporine
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Wyeth-Ayerst anticipates filing a supplemental NDA at the beginning of next year for a new Rapamune renal post-transplant regimen that will minimize or eliminate cyclosporine use.